选择性U-II受体对抗剂在完整和剥离大动脉的糖尿病大鼠中修改血管功能的作用
Sonia Sh Abdulfatah1, Ridha H Hussein2
1Biology Department, College of Science, Sulaimani University, Sulaimani, Iraq.
Journal of receptor and signal transduction research
|January 12, 2026
概括
选择性UT抗剂乌兰提德和帕洛苏兰可以降低尿素II (U-II) 诱导的血管收缩. 这两种药物都显示出糖尿病血管病的治疗潜力,对U-II反应有明显的影响.
科学领域:
- 血管药理学 血管药理学
- 内分泌学 在内分泌学.
- 糖尿病并发症 糖尿病并发症
背景情况:
- 尿素-II (U-II) 是一种强大的血管收缩剂,通过UT受体起作用.
- 内皮缓冲通常可以防止U-II信号传输,但在糖尿病中会受到损害,导致血管功能障碍.
- 选择性UT抗剂如Urantide和Palosuran是有前途的治疗药物,但糖尿病患者的比较数据有限.
研究的目的:
- 为了比较Urantide和Palosuran对大鼠大动脉中U-II诱导的血管收缩的影响.
- 在非糖尿病和糖尿病的老鼠模型中研究这些效应.
- 评估内皮在调解U-II反应和抗体活性中的作用.
主要方法:
- 来自非糖尿病和糖尿病老鼠的胸前大动脉环的同度记录.
- 产生尿素II度-反应曲线 (10^-11到10^-8M).
- 评估乌兰和帕洛苏兰 (1μM) 对U-II诱导的收缩与完整和剥离的内皮的影响.
主要成果:
- 内皮损失显著增加了非糖尿病主动脉的U-II收缩,并显示了糖尿病血管的高反应性.
- 乌兰提德完全取消了U-II的有效性.
- 帕洛苏兰减弱了U-II的有效性和强度,在糖尿病患者脱落的大动脉环中显示出更大的抑制.
结论:
- 管受体对抗作用有效抑制了U-II介导的血管反应.
- 乌兰提德和帕洛苏兰在它们的对抗中表现出明显的药理学特征.
- 这些发现突出了UT抗剂在治疗糖尿病血管病变中的治疗潜力.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909
01:23Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
01:31Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K